Phase 2 N=48 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Phase 1 N=164 BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Neoplasms
Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
N/A N=13 Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
Phase 2 N=66 Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Phase 2 N=162 Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Breast Cancer
Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011
Phase 2 N=9 Palbociclib With Everolimus + Exemestane In BC
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Hormone Receptor (HR)-Positive Breast Cancer
Primary: Clinical Benefit Rate (CBR) [Phase 2a] — 6 Participants
Phase 2 N=70 Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
Breast Cancer · Metastasis
Primary: Number of Participants With Objective Response — 0; 1; 1; 1 participants
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 3 N=235 Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Post Menopausal Breast Cancer
Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Phase 1 N=35 Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2 participants
Phase 2 N=118 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Metastatic Breast Carcinoma · Stage IIIB Breast Cancer AJCC v7 · Stage IIIC Breast Cancer AJCC v7
Primary: Number of Participants With Progression Free Survival (PFS) at 12 Months — 8; 16 Participants
Phase 3 N=724 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Breast Cancer
Primary: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. — 6.93; 2.83 months — p=<0.0001
Phase 2 N=49 Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Estrogen Receptor Positive Breast Cancer
Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months
Phase 2 N=131 Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Metastatic Breast Cancer
Primary: Progression-free Survival — 10.3; 5.1 months — p=0.02
Phase 4 N=52 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Oestrogen Receptor Positive Advanced Breast Cancer
Primary: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer — 39…
Phase 2 N=71 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Phase 2 N=183 Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Primary: Phase 1b and Phase 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 3; 90; 82…
Phase 2 N=33 Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Breast Cancer
Primary: Time to Progression — 7.4 months
Phase 3 N=315 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
HER2-Positive Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma · Stage IB Breast Cancer AJCC v7
Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Phase 2 N=36 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Phase 2 N=47 Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
Breast Cancer
Primary: Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) — 11.0 percent change in SUV
Phase 3 N=369 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Neoplasms, Breast
Primary: Progression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI) — 62; 75; 7; 3 Participants…
Phase 2 N=93 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Estrogen Receptor-positive Breast Cancer · HER2/Neu Negative · Stage IV Breast Cancer AJCC v6 and v7
Primary: Incidence of Adverse Events — 0.756 proportion of patients
Phase 2 N=58 Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) Until First Progression — 2.0; 5.7 months